Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Deferred Revenue (2021 - 2025)

Historic Current Deferred Revenue for Autolus Therapeutics (AUTL) over the last 5 years, with Q3 2025 value amounting to $7.6 million.

  • Autolus Therapeutics' Current Deferred Revenue fell 9625.76% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 9625.76%. This contributed to the annual value of $35.0 million for FY2022, which is 2553.19% down from last year.
  • Autolus Therapeutics' Current Deferred Revenue amounted to $7.6 million in Q3 2025, which was down 9625.76% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Current Deferred Revenue ranged from a high of $219.4 million in Q1 2025 and a low of $2.1 million during Q2 2025
  • Moreover, its 5-year median value for Current Deferred Revenue was $140.8 million (2023), whereas its average is $115.5 million.
  • In the last 5 years, Autolus Therapeutics' Current Deferred Revenue surged by 4446.02% in 2024 and then tumbled by 9892.8% in 2025.
  • Autolus Therapeutics' Current Deferred Revenue (Quarter) stood at $47.0 million in 2021, then decreased by 25.53% to $35.0 million in 2022, then skyrocketed by 302.29% to $140.8 million in 2023, then surged by 44.46% to $203.4 million in 2024, then plummeted by 96.26% to $7.6 million in 2025.
  • Its Current Deferred Revenue stands at $7.6 million for Q3 2025, versus $2.1 million for Q2 2025 and $219.4 million for Q1 2025.